Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Brain Neoplasms × defactinib × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1 CNS 1

Conditions

Uveal Melanoma 1 Melanoma 1 Brain Neoplasms 1

Interventions

Radiosurgery 21 Ipilimumab 14 Nivolumab 13 pembrolizumab 11 Temozolomide 8 encorafenib 7 dabrafenib 7 binimetinib 7 Magnetic Resonance Spectroscopy 6 trametinib 5 Bevacizumab 5 cobimetinib 3 Thalidomide 3 Radiotherapy 3 cediranib 2 Vemurafenib 2 Spermine Synthase 2 Specimen Handling 2 Radiation 2 Paclitaxel 2 Opdualag 2 CTLA-4 Antigen 2 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2 14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 2 relatlimab 1 regorafenib 1 paclitaxel-Angiopep-2 conjugate 1 motexafin gadolinium 1 lenvatinib 1 glutathione pegylated liposomal doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06194929 2025-12-03

DETERMINE

University of Utah

Phase 1/2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡